×
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing anti...
https://doi.org/10.1186/s13073-021-00985-w 10.1038/s41586-020-2008-3 10.23822/EurAnnACI.1764-1489.173 10.1038/s41586-020-2852-1 10.1038/s41586-020-2180-5 10.1016/j.cell.2020.09.037 10.1016/j.cell.2021.01.037 10.1016/S1473-3099(21)00078-5 10.1126/science.abd0831 10.1016/j.chom.2021.01.014 10.1136/bmj.n504 10.1016/j.cell.2021.03.036 10.1038/s41591-021-01318-5 10.1016/j.cell.2021.02.037 10.1136/bmj.n359 10.1073/pnas.160252097 10.1074/jbc.M605197200 10.1073/pnas.1614942113 10.1038/s41423-020-0403-1 10.1038/nprot.2009.3 10.1038/s41423-020-0458-z 10.1038/s41467-021-21213-4 10.1186/s12859-015-0548-6 10.1093/nar/gku411 10.1093/molbev/msw054 10.1093/bioinformatics/btm404 10.24272/j.issn.2095-8137.2020.065 10.1016/j.gpb.2020.09.001 10.1002/gch2.1018 10.1126/science.abc5902 10.1038/s41586-020-2456-9 10.1016/j.cell.2020.09.049 10.1038/s41586-020-2349-y 10.1016/j.immuni.2020.10.023 10.1038/s41586-020-2381-y 10.1126/science.abb7269 10.1038/nm.3743 10.1016/j.cell.2020.05.025 10.1016/j.cell.2020.06.025 10.1126/science.abd2321 10.1126/science.abc2241 10.1038/s41467-021-21767-3 10.1016/j.cell.2020.08.012 10.1038/s41564-020-0771-4 10.1016/S0140-6736(20)30251-8 10.1042/BJ20121221 10.1038/s41586-020-2895-3 10.1126/science.abc4730 10.1016/j.bbrc.2020.10.012 10.1016/j.cell.2021.02.032 10.1016/j.xcrm.2021.100255 10.1016/j.cell.2020.07.012 10.1126/science.abf9302 10.1126/science.1244730 10.1128/JVI.78.16.8946-8949.2004
Genome Medicine; Yi C, Sun X et. al.

Oct 16th, 2021 - The receptor-binding domain (RBD) variants of SARS-CoV-2 could impair antibody-mediated neutralization of the virus by host immunity; thus, prospective surveillance of antibody escape mutants and understanding the evolution of RBD are urgently needed. Using the single B cell cloning technology, we isolated and characterized 93 RBD-specific antibodies from the memory B cells of four COVID-19 con...

Critical concepts for COVID-19 Mass Vaccination Site Operations.
https://doi.org/10.1017/dmp.2021.319
Disaster Medicine and Public Health Preparedness; Goldberg SA, Callaway D et. al.

Oct 16th, 2021 - Mass vaccination campaigns have been used effectively to limit the impact of communicable disease on public health. However, the scale of the COVID19 vaccination campaign is unprecedented. Mass vaccination sites consolidate resources and experience into a single entity and are essential to achieving community ("herd") immunity rapidly, efficiently, and equitably. Healthcare systems, local and r...

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-...
https://doi.org/10.1038/s41591-021-01548-7 10.1038/s41591-021-01446-y 10.1136/bmj.n1943 10.15585/mmwr.mm7013e3 10.1056/NEJMoa2108891 10.1097/EDE.0000000000001366 10.1016/S0140-6736(21)01358-1 10.1016/S2468-2667(20)30282-6 10.1038/s41591-021-01410-w 10.1038/s41564-021-00947-3 10.1056/NEJMe2110605 10.1016/S0140-6736(21)00947-8 10.1038/s41577-020-00434-6 10.1038/s41586-020-2608-y 10.1016/j.cell.2020.08.026 10.1126/science.abh0635 10.7554/eLife.64683
Nature Medicine; Pouwels KB, Pritchard E et. al.

Oct 16th, 2021 - The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, given the increasingly dominant B.1.617.2 (Delta) variant. In this study, we investigated the effectiveness of these vaccines in a large, community-based survey of randomly selected households across the United Kingdom. We ...

A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third...
https://doi.org/10.1007/s00259-021-05579-7 10.1056/NEJMoa2034577 10.1056/NEJMoa2101765 10.1056/NEJMc2100362 10.1016/j.ccell.2021.06.002 10.1182/blood.2021011568 10.1016/j.ccell.2021.06.009 10.1007/s00259-021-05314-2 10.1148/radiol.2021210886 10.1007/s00330-021-08122-2 10.1148/radiol.2021210275 10.1007/s00259-021-05331-1 10.1148/radiol.2021210436 10.1007/s00259-021-05389-x 10.2967/jnumed.121.262194 10.3390/ph14080762 10.1038/s41586-021-03739-1 10.1182/bloodadvances.2021005094
European Journal of Nuclear Medicine and Molecular Imaging; Cohen D, Hazut Krauthammer S et. al.

Oct 16th, 2021 - The incidence of COVID-19 vaccine-associated hypermetabolic lymphadenopathy (VAHL) is high following the administration of the first and second BNT162b2 vaccine doses. The impact of this finding on [18F]FDG PET-CT interpretation and its correlation with the induced humoral immunity have been reported. Assuming the amnestic immune response is different following the third vaccine dose, we aimed ...

Similarities and differences between multiple sclerosis and type 1 diabetes.
https://doi.org/10.1002/dmrr.3505
Diabetes/metabolism Research and Reviews; Pozzilli V, Grasso EA et. al.

Oct 16th, 2021 - Multiple sclerosis (MS) and type 1 diabetes (T1D) are chronic conditions that result from dysfunction of the immune system. Their common root in autoimmunity stimulates interest in the exploration of similarities and differences between the two diseases. Genetic susceptibility is relevant, creating a substrate, on which environmental factors act as a trigger of an aberrant immune response. Desp...

FDA Panel Endorses Booster for All J&J Recipients
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/95080

Oct 15th, 2021 - Despite limited available data, an FDA advisory panel recommended a booster dose of Johnson & Johnson's COVID-19 vaccine for all individuals who received the single-dose vaccine, to be given at least 2 months after the initial dose. The FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 19-0 that the booster dose at this interval was safe and effective for individu...

FDA Panel Backs Second Shot for Those Who Got J&J Vaccine 
https://www.medscape.com/viewarticle/961003

Oct 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. A US Food and Drug Administration (FDA) advisory committee on Friday voted 19-0 to authorize second doses of the Johnson & Johnson COVID-19 vaccine in an effort to boost immunity. It was the second vote in as many days to back a change to a COVID vaccine timeline. In its vote, the committee said...

Lessons in self-defence: inhibition of virus entry by intrinsic immunity.
https://doi.org/10.1038/s41577-021-00626-8 10.1159/000478729 10.1038/nrmicro817 10.1080/10409230802058320 10.1016/j.cell.2006.02.007 10.1038/ni1125 10.1038/ni.2229 10.1126/science.1233028 10.1038/nri1604 10.1371/journal.pbio.1000301 10.1146/annurev-genet-110711-155522 10.1098/rstb.2012.0496 10.1038/nri3295 10.1016/j.cell.2009.12.017 10.1371/journal.ppat.1002337 10.1371/journal.ppat.1003124 10.1371/journal.ppat.1001258 10.1128/JVI.02003-18 10.1128/JVI.01551-16 10.1099/vir.0.066555-0 10.1371/journal.pone.0080723 10.1002/hep.26066 10.1074/jbc.M115.657346 10.1128/JVI.05633-11 10.15252/embj.201695597 10.1016/j.celrep.2016.05.074 10.1002/hep.30699 10.1128/JVI.02199-09 10.1093/infdis/jiv255 10.1084/jem.20161270 10.1128/JVI.03382-12 10.1111/tra.12416 10.1128/JVI.00655-16 10.26508/lsa.202000909 10.1128/JVI.01531-10 10.1371/journal.pone.0156739 10.1016/j.virol.2014.10.015 10.1016/j.chom.2016.08.006 10.3390/v6093683 10.1128/JVI.02422-20 10.1128/JVI.00562-20 10.1038/nri3344 10.1371/journal.pone.0096579 10.15252/embr.201642771 10.1038/nature10921 10.1038/nm.4370 10.1093/infdis/jiaa224 10.7717/peerj.10402 10.1371/journal.ppat.1002909 10.1073/pnas.1900784116 10.1128/JVI.00581-16 10.1007/s40588-018-0103-0 10.1371/journal.ppat.1004048 10.1128/JVI.00481-13 10.7554/eLife.58537 10.15252/embr.201744100 10.1038/srep24029 10.1021/acsnano.0c10567 10.1016/j.celrep.2013.10.033 10.1007/s00249-014-0983-8 10.1074/jbc.M114.557694 10.2217/fmb.14.65 10.1128/JVI.01828-12 10.1111/cmi.12262 10.1073/pnas.1811892115 10.7554/eLife.39823 10.1371/journal.pone.0118794 10.1074/jbc.M114.630780 10.1038/nchembio.405 10.1074/jbc.M112.362095 10.1021/acschembio.1c00013 10.26508/lsa.201900542 10.1038/s41589-018-0213-2 10.1371/journal.ppat.1007532 10.1111/cmi.12339 10.1016/j.ymthe.2020.09.026 10.1016/j.cub.2021.06.022 10.3390/ijms20163859 10.1371/journal.ppat.1005095 10.1016/j.chembiol.2020.03.004 10.1038/nrm1591 10.1016/j.chom.2013.03.006 10.1097/MOL.0000000000000506 10.1016/j.celrep.2017.05.028 10.1074/jbc.M201191200 10.1371/journal.pone.0000851 10.1128/mBio.01345-18 10.1177/1753425912443392 10.1074/jbc.M117.783878 10.1016/j.chemphyslip.2016.05.003 10.1074/jbc.M112.438515 10.1073/pnas.2012197117 10.1128/JVI.03372-12 10.1038/s41467-021-24817-y 10.1073/pnas.1320856111 10.1172/JCI84889 10.1073/pnas.192460799 10.1038/nature04019 10.1016/j.cell.2015.11.053 10.1089/dna.2017.3791 10.1101/2021.04.12.439453v1 10.1128/JVI.00560-08 10.3390/v12070727 10.1016/j.chom.2013.09.010 10.1038/s41564-020-0701-5 10.1073/pnas.1114981109 10.1016/j.immuni.2012.11.005 10.1073/pnas.0909142106 10.1074/jbc.M807210200 10.1016/j.immuni.2017.02.012 10.1073/pnas.1404271111 10.1038/srep07242 10.1128/JVI.01047-18 10.1093/intimm/6.12.1967 10.4049/jimmunol.1401249 10.1038/nature09907 10.1038/s41564-020-0769-y 10.1073/pnas.1720032115 10.1038/s41467-018-06000-y 10.1074/jbc.M116.755819 10.1016/j.cytogfr.2014.07.015 10.1186/1471-2121-8-13 10.1128/MCB.22.10.3358-3372.2002 10.1089/jir.2014.0115 10.1038/s41564-018-0273-9 10.1016/j.coi.2012.11.006 10.1073/pnas.97.2.745 10.1126/science.1189176 10.1080/22221751.2019.1677446 10.1128/JVI.03398-14 10.18632/oncotarget.12104 10.1016/j.molmed.2017.08.005 10.1126/science.abe2977 10.1126/science.abb3753 10.3390/ijms20092209 10.1371/journal.ppat.1005150 10.1016/0092-8674(78)90282-9 10.1128/MCB.00537-16 10.3389/fimmu.2017.01853 10.1016/j.bbamcr.2018.09.012 10.1186/s12977-017-0377-y 10.1016/j.celrep.2017.07.060 10.1126/sciimmunol.aai8071 10.1091/mbc.e05-03-0204 10.1016/S0021-9258(19)61440-7 10.1016/j.stem.2020.10.005 10.1099/jgv.0.000954 10.1111/tra.12389 10.1038/nri3787 10.1016/j.chom.2020.05.008 10.1146/annurev-virology-092818-015756
Nature Reviews. Immunology; Majdoul S, Compton AA

Oct 15th, 2021 - Virus entry, consisting of attachment to and penetration into the host target cell, is the first step of the virus life cycle and is a critical 'do or die' event that governs virus emergence in host populations. Most antiviral vaccines induce neutralizing antibodies that prevent virus entry into cells. However, while the prevention of virus invasion by humoral immunity is well appreciated, cons...

Protective Immunity after Natural Infection with Severe Acute Respiratory Syndrome Coro...
https://doi.org/10.1016/j.ijid.2021.10.010
International Journal of Infectious Diseases : IJID : Off... Spicer KB, Glick C et. al.

Oct 15th, 2021 - As vaccine supply and access remain limited in many parts of the world, understanding the duration of protection from reinfection after natural infection is important. Distinct individuals testing positive and negative for SARS-CoV-2 between March 6, 2020, and August 31, 2020, in Kentucky, USA, were identified using the Kentucky National Electronic Disease Surveillance System. Individuals were ...

Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotype...
https://doi.org/10.1084/jem.20211327
The Journal of Experimental Medicine; Lu X, Hosono Y et. al.

Oct 15th, 2021 - Adaptive immunity is a fundamental component in controlling COVID-19. In this process, follicular helper T (Tfh) cells are a subset of CD4+ T cells that mediate the production of protective antibodies; however, the SARS-CoV-2 epitopes activating Tfh cells are not well characterized. Here, we identified and crystallized TCRs of public circulating Tfh (cTfh) clonotypes that are expanded in patien...

New Pandemic Origin Probe; A First for CMS and LGBTQ Care; COVID-Flu Jab Mix-up
https://www.medpagetoday.com/infectiousdisease/covid19/95034

Oct 14th, 2021 - Note that some links may require registration or subscription. The WHO released its proposed roster of scientific advisors who have the "last chance" to conduct an official inquiry into the origin of how SARS-CoV-2 came to infect humans. (Reuters) Black Americans are catching up in COVID vaccination rates. (New York Times) Apple seeks to make AirPods a wearable health device. (Wall Street Journ...

FDA Advisors Vote to Recommend Moderna Boosters
https://www.medscape.com/viewarticle/960915

Oct 14th, 2021 - Editor's note: This story was updated Thursday October 14, 6:45 PM A panel of experts that advises the FDA on vaccine decisions voted unanimously Thursday to approve booster doses of Moderna's COVID-19 vaccine. The 19 members of the FDA's Vaccines and Related Biological Products Advisory Committee voted to authorize a 50-milligram dose — half the dose used in the primary series of shots — to bo...

Mixing COVID Vaccine Boosters May Be Better Option: Study
https://www.medscape.com/viewarticle/960932

Oct 14th, 2021 - A new US government study shows it isn't risky and may even be a good idea to mix, rather than match, COVID-19 vaccines when getting a booster dose. The study also shows mixing different kinds of vaccines appears to spur the body to make higher levels of virus-blocking antibodies than they would have gotten by boosting with a dose of the vaccine the person already had. If regulators endorse the...

Passport to a Mighty Nation: Exploring Sociocultural Foundation of Chinese Public's Att...
https://doi.org/10.3390/ijerph181910439
International Journal of Environmental Research and Publi... Hu M, Jia H et. al.

Oct 14th, 2021 - Vaccination against COVID-19 is essential against the pandemic. There are broad discussions on adopting certificates for vaccination and the immunity obtained after infection. Based on a national sample of over 2000 participants administered in April 2021, the current study examines the Chinese public's attitudes to the so-called COVID-19 vaccination passport and factors contributing to their v...

SARS-CoV-2 targeting by RNAi and host complement inhibition: A two-pronged subterfuge f...
https://doi.org/10.1002/iid3.549
Immunity, Inflammation and Disease; Naqvi RA, Shukla D et. al.

Oct 14th, 2021 - The lack of knowledge about the specific preventive measures and limited scientific information on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to an excruciating onset and progression of coronavirus disease 2019 (COVID-19). Swift development of various successful vaccines around the globe is striving to contain the exponential surges of COVID-19 cases. However, the ongoing ...

Caregiver Willingness to Vaccinate Their Children against COVID-19 after Adult Vaccine ...
https://doi.org/10.3390/ijerph181910224
International Journal of Environmental Research and Publi... Goldman RD, Krupik D et. al.

Oct 14th, 2021 - Vaccines against COVID-19 are likely to be approved for children under 12 years in the near future. Understanding vaccine hesitancy in parents is essential for reaching herd immunity. A cross-sectional survey of caregivers in 12 emergency departments (ED) was undertaken in the U.S., Canada, and Israel. We compared reported willingness to vaccinate children against COVID-19 with an initial surve...

Even One Vaccinated Member Can Cut Family's COVID Risk
https://www.medscape.com/viewarticle/960780

Oct 13th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The chances that unvaccinated family members will be infected or hospitalized with COVID-19 drop sharply if even one family member is vaccinated. The chances are reduced even further with each additional vaccinated or otherwise immune family member, according to new data. Dr Peter Nordström Lead...

FDA Questions Reliability of Data Backing J & J's Bid for Boosters
https://www.medscape.com/viewarticle/960825

Oct 13th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The US Food and Drug Administration (FDA) said Johnson & Johnson may have to put its thumb on the scale when making its case to an advisory panel on Friday to market boosters for its single-dose vaccine. Johnson & Johnson, together with its partner Janssen, has asked the FDA to authorize a secon...

Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after CO...
https://doi.org/10.1111/hiv.13188
HIV Medicine; Tuan JJ, Zapata H et. al.

Oct 12th, 2021 - Effective and safe COVID-19 vaccines have been developed and have resulted in decreased incidence and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and can decrease secondary transmission. However, there are concerns about dampened immune responses to COVID-19 vaccination among immunocompromised patients, including people living with HIV (PLWH), which may bl...

Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Im...
https://doi.org/10.1001/jamainternmed.2021.5814
JAMA Internal Medicine; Nordström P, Ballin M et. al.

Oct 12th, 2021 - The association between COVID-19 immunity within families and the risk of infection in nonimmune family members is unknown. To investigate the association between risk of COVID-19 in nonimmune individuals and the number of their family members with known immunity acquired from a previous COVID-19 infection or full vaccination (2 vaccine doses). In this cohort study of data from nationwide regis...